| A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers KN Kodumudi, K Woan, DL Gilvary, E Sahakian, S Wei, JY Djeu Clinical cancer research 16 (18), 4583-4594, 2010 | 584 | 2010 |
| The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells M Zemskova, E Sahakian, S Bashkirova, M Lilly Journal of Biological Chemistry 283 (30), 20635-20644, 2008 | 151 | 2008 |
| Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of … T Knox, E Sahakian, D Banik, M Hadley, E Palmer, S Noonepalle, J Kim, ... Scientific reports 9 (1), 6136, 2019 | 150 | 2019 |
| Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation KV Woan, M Lienlaf, P Perez-Villaroel, C Lee, F Cheng, T Knox, ... Molecular oncology 9 (7), 1447-1457, 2015 | 146 | 2015 |
| Essential role of HDAC6 in the regulation of PD-L1 in melanoma M Lienlaf, P Perez-Villarroel, T Knox, M Pabon, E Sahakian, J Powers, ... Molecular oncology 10 (5), 735-750, 2016 | 144 | 2016 |
| Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75 M Mediavilla-Varela, FJ Pacheco, F Almaguel, J Perez, E Sahakian, ... Molecular cancer 8, 1-15, 2009 | 133 | 2009 |
| Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function E Sahakian, JJ Powers, J Chen, SL Deng, F Cheng, A Distler, DM Woods, ... Molecular immunology 63 (2), 579-585, 2015 | 128 | 2015 |
| IL-7 Dependence in human B lymphopoiesis increases during progression of ontogeny from cord blood to bone marrow YK Parrish, I Baez, TA Milford, A Benitez, N Galloway, JW Rogerio, ... The Journal of Immunology 182 (7), 4255-4266, 2009 | 118 | 2009 |
| A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs F Cheng, M Lienlaf, HW Wang, P Perez-Villarroel, C Lee, K Woan, ... The Journal of Immunology 193 (6), 2850-2862, 2014 | 114 | 2014 |
| Modulation of antigen‐presenting cells by HDAC inhibitors: implications in autoimmunity and cancer KV Woan, E Sahakian, EM Sotomayor, E Seto, A Villagra Immunology and cell biology 90 (1), 55-65, 2012 | 80 | 2012 |
| Cancer immunotherapy: immune suppression and tumor growth GC Prendergast, EM Jaffee Academic Press, 2013 | 76 | 2013 |
| Induction of clusterin by AKT—role in cytoprotection against docetaxel in prostate tumor cells B Zhong, DA Sallman, DL Gilvary, D Pernazza, E Sahakian, D Fritz, ... Molecular cancer therapeutics 9 (6), 1831-1841, 2010 | 74 | 2010 |
| Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10 H Wang, F Cheng, K Woan, E Sahakian, O Merino, J Rock-Klotz, ... The Journal of Immunology 186 (7), 3986-3996, 2011 | 66 | 2011 |
| Ikaros isoform x is selectively expressed in myeloid differentiation KJ Payne, G Huang, E Sahakian, JY Zhu, NS Barteneva, LW Barsky, ... The Journal of Immunology 170 (6), 3091-3098, 2003 | 66 | 2003 |
| The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells K Maharaj, JJ Powers, A Achille, M Mediavilla-Varela, W Gamal, ... Blood advances 4 (13), 3072-3084, 2020 | 63 | 2020 |
| Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology E Sahakian, J Chen, JJ Powers, X Chen, K Maharaj, SL Deng, AN Achille, ... Journal of leukocyte biology 102 (2), 475-486, 2017 | 56 | 2017 |
| A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. PIJ Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland ... Leukemia Research 10 (74), 89-96, 2018 | 51* | 2018 |
| HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms L Yue, V Sharma, NP Horvat, AA Akuffo, MS Beatty, C Murdun, C Colin, ... Blood, The Journal of the American Society of Hematology 135 (3), 191-207, 2020 | 50 | 2020 |
| Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma SN Quayle, SS Jones, EM Sotomayor, J Pinilla-Ibarz, E Sahakian US Patent App. 14/508,135, 2015 | 43 | 2015 |
| Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia JC Chavez, E Sahakian, J Pinilla-Ibarz Core evidence, 37-45, 2013 | 30 | 2013 |
John J. PowersResearch Lab Coordinator, Moffitt Cancer Center在 moffitt.org 的电子邮件经过验证
